Being overweight is not only bad for one’s health – it also costs society a lot of money. Every year, the Belgian government loses at least 4.5 billion euros due to the direct and indirect costs linked to excessive weight and obesity. As with COVID-19, this issue needs to be tackled as a public health concern: the responsibility of both individuals and policymakers.
Ghent-based Indigo aims to make a huge difference to the quality of life of people with diabetes. The company is developing a device to render the monitoring of blood sugar levels painless and invisible, a major improvement compared to the tools available today. The innovative technology is based on spectroscopy – using light to measure glucose levels through the skin.
Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of the Board. The company also expands the Scientific Advisory Board with clinical experts to support broader therapeutic applications, exploring the potential of novel HDAC6 inhibitors in Charcot-Marie-Tooth disease (CMT), and now also in other indications such as chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS).
The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.
The arrival of gene therapy in the ‘90s brought hope for the treatment of genetic diseases. In recent years, new and emerging technologies have allowed us to overcome initial limitations, opening up the potential of tackling health conditions that were impossible to treat just a few years ago. Stargardt disease – a form of inherited blindness – is one such genetic condition, where researchers in the EU project StarT are working on novel gene therapy approaches to eventually help patients.
Being overweight is not only bad for one’s health – it also costs society a lot of money. Every year, the Belgian government loses at least 4.5 billion euros due to the direct and indirect costs linked to excessive weight and obesity. As with COVID-19, this issue needs to be tackled as a public health concern: the responsibility of both individuals and policymakers.
Ghent-based Indigo aims to make a huge difference to the quality of life of people with diabetes. The company is developing a device to render the monitoring of blood sugar levels painless and invisible, a major improvement compared to the tools available today. The innovative technology is based on spectroscopy – using light to measure glucose levels through the skin.
Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints Gerhard Koenig as Chairman of the Board. The company also expands the Scientific Advisory Board with clinical experts to support broader therapeutic applications, exploring the potential of novel HDAC6 inhibitors in Charcot-Marie-Tooth disease (CMT), and now also in other indications such as chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS).
The radioisotope Actinium-225 shows clear promise in the battle against cancer, but to fulfil its potential we will need to enable large-scale production of the rare substance. A collaboration between IBA – the world’s leading company in particle accelerator technology – and the Belgian Nuclear Research Center (SCK CEN) now makes this crucial step possible. The partners are constructing a production plant on the SCK CEN site in the Flemish city of Mol.
The arrival of gene therapy in the ‘90s brought hope for the treatment of genetic diseases. In recent years, new and emerging technologies have allowed us to overcome initial limitations, opening up the potential of tackling health conditions that were impossible to treat just a few years ago. Stargardt disease – a form of inherited blindness – is one such genetic condition, where researchers in the EU project StarT are working on novel gene therapy approaches to eventually help patients.